Health & Fitness
Health and Fitness
Health and Fitness 
Mon, February 7, 2011
Sun, February 6, 2011
Sat, February 5, 2011
Fri, February 4, 2011
SANTA CLARA, Calif.--([ BUSINESS WIRE ])--XenoPort, Inc. (Nasdaq: XNPT) reported today that equity awards were made to three new employees subject to the terms and conditions of the XenoPort 2010 Inducement Award Plan. The employees were granted restricted stock units representing an aggregate of 950 shares of XenoPorta™s common stock. The restricted stock units vest in four equal annual installments on anniversaries of the February 1, 2011 grant date. The equity awards were approved by the independent compensation committee of XenoPorta™s board of directors and were granted as an inducement material to the new employees entering into employment with XenoPort in accordance with Nasdaq Market Place Rule 5635(c)(4).
About XenoPort
XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the bodya™s natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in collaboration with Astellas Pharma Inc. and GlaxoSmithKline. XenoPorta™s product candidates are being studied for the potential treatment of restless legs syndrome, gastroesophageal reflux disease, neuropathic pain, spasticity and Parkinsona™s disease.
To learn more about XenoPort, please visit the Web site at [ www.XenoPort.com ].
XenoPort is a registered trademark of XenoPort, Inc.
XNPT2G